34 results about "Iliac artery thrombosis" patented technology

The novel amidino derivatives of the formula (I):wherein all the symbols are as in specification defined;have an inhibitory activity of a blood coagulation factor VIIa and are useful for treatment and / or prevention of several angiopathy caused by enhancing a coagulation activity, such as disseminated intravascular coagulation, coronary thrombosis, cerebral infarction, cerebral embolism, transient ischemic attack, cerebrovascular disorders, pulmonary vascular diseases, deep venous thrombosis, peripheral arterial obstruction, thrombosis after artificial vascular transplantation and artificial valve transplantation, post-operative thrombosis, reobstruction and restenosis after coronary artery bypass operation, reobstruction and restenosis after PTCA or PTCR, thrombosis by extracorporeal circulation and procoagulative diseases such as glomerlonephriitis.

A method is disclosed for preventing arterial thrombosis in a subject comprising administering to said subject a therapeutically effective amount of an antibody or epitope-binding fragment or derivative thereof, wherein said antibody, fragment or derivative specifically binds to activated Factor XIIa and prevents the interaction of activated Factor XIIa with its physiological substrates.

The present invention relates to a method for establishing a diagnosis if an individual has suffered from or a prognosis if an individual is at risk of suffering from a coronary heart event, which method comprises determining the concentration of sCD40L in a body fluid of the individual; determining the concentration of a proximal inflammatory marker, preferably PAPP-A or Lp-PLA2 comparing the values obtained with reference values; and establishing the diagnosis or the prognosis in respect to the cardiovascular event. The combination according to the invention can be used with further markers selected from further inflammatory markers, anti-inflammatory markers and / or neurohumoral markers.

The invention discloses a medicinal composition for treating cardiovascular diseases and a preparation method thereof. The medicinal composition is prepared from the following active pharmaceutical ingredients: ginseng stem and leaf, ginkgo leaf, total saponin extract of ginseng stem and leaf, and ginkgo leaf extract. The medicinal composition can effectively resist rat infarction and myocardial ischemia injury of acute myocardial infarction, reduce the myocardial infarction area, enhance the hypoxia resistance of cardiac muscles, improve the function of vascular endothelium and resist arterial thrombosis. The synergic experiment indicates that the active pharmaceutical ingredients (ginseng stem and leaf and ginkgo leaf) medicinal composition have an synergic action, and have much better effect as compared with single ginseng stem and leaf or ginkgo leaf. The medicinal composition has the advantages of low toxicity, high safety and high stability.

[Object] To provide an excellent pharmaceutical composition for preventing and / or treating vascular diseases.[Means for Solution] Useful to provide a pharmaceutical composition for preventing and / or treating vascular diseases, which comprises 1) a COX-1 selective inhibitor and 2) clopidogrel or a pharmaceutically acceptable salt thereof. The present invention is useful as an excellent pharmaceutical composition for preventing and / or treating vascular diseases is provided and is particularly useful as a pharmaceutical composition for preventing and / or treating arterial thrombosis, ischemic heart disease, ischemic brain disease, pulmonary embolism, peripheral circulation disorder, restenosis and reocclusion, essential thrombocytosis and so on is provided.

The present invention is related to heparin-like compounds characterized by their capacity of inhibiting collagen-induced platelet aggregation in flowing whole blood and their use for prophylactic treatment of arterial thrombosis associated with vascular or microvascular injury and interventions. Said properties are related to a high coupling density of negatively charged heparin or heparin-like glycosaminoglycan molecules, present in multiple heparin or heparin-like glycosaminoglycans as well as in proteoglycans containing said multiple heparin or heparin-like glycosaminoglycans or lower-molecular-weight heparin or heparin-like glycosaminoglycans connected directly or through spacer / linker molecules to globular core molecules. Heparin-like compounds, with said properties are obtainable from mammalian mast cells, by tissue extraction or cell cultivation. The heparin-like compounds of the present invention can also be produced by synthetical, semisynthetical and / or biotechnological methods and they are useful for manufacturing preparations, means and devices for local or topical application in prophylactic treatment of arterial thrombosis and its sequelae.

The present invention is related to heparin-like compounds characterized by their capacity of inhibiting collagen-induced platelet aggregation in flowing whole blood and their use for prophylactic treatment of arterial thrombosis associated with vascular or microvascular injury and interventions. Said properties are related to a high coupling density of negatively charged heparin or heparin-like glycosaminoglycan molecules, present in multiple heparin or heparin-like glycosaminoglycans as well as in proteoglycans containing said multiple heparin or heparin-like glycosaminoglycans or lower-molecular-weight heparin or heparin-like glycosaminoglycans connected directly or through spacer / linker molecules to globular core molecules. Heparin-like compounds, with said properties are obtainable from mammalian mast cells, by tissue extraction or cell cultivation. The heparin-like compounds of the present invention can also be produced by synthetical, semisynthetical and / or biotechnological methods and they are useful for manufacturing preparations, means and devices for local or topical application in prophylactic treatment of arterial thrombosis and its sequelae.

The present invention is directed to certain amides and heterocyclic compounds. The present invention also relates to uses of these compounds to treat several diseases including autoimmune disorders, cardiovascular disorders, inflammation, central nervous system disorders, arterial thrombotic disorders, fibrotic disorders, glaucoma, and neoplastic disorders.

Provided herein is an animal having a persistent hypercoagulable state by implanting a cell, for example a tumor cell, in which the gene of human tissue factor is implanted to an experimental animal such as a mouse and then growing the cell, thereby persistently supplying human tissue factor to the experimental animal. This animal model is useful for research and development of therapeutic agents for diseases having a persistent hypercoagulable state. Also provided are preventive or therapeutic agents for diseases having a persistent hypercoagulable state, a hypercoagulable state resulting from infections, venous thrombosis, arterial thrombosis, and diseases resulting from the hypertrophy of vascular media, the agent comprising an antibody against human tissue factor (human TF) as an active ingredient.

Provided are compounds, methods, and pharmaceutical compositions for reducing the amount or activity of FXI RNA in a cell or subject, and in certain instances reducing the amount of FXI protein in a cell or subject. Such compounds, methods, and pharmaceutical compositions are useful to prevent, treat, or ameliorate at least one symptom of a thromboembolic condition without a significant increase in a bleeding risk. Such thromboembolic conditions include deep vein thrombosis, venous or arterial thrombosis, pulmonary embolism, myocardial infarction, stroke, thrombosis associated with chronic kidney disease or end-stage renal disease (ESRD), including thrombosis associated with dialysis, or other procoagulant condition. Such symptoms include decreased blood flow through an affected vessel, death of tissue, and death.

The present invention is directed to certain amides and heterocyclic compounds. The present invention also relates to uses of these compounds to treat several diseases including autoimmune disorders, cardiovascular disorders, inflammation, central nervous system disorders, arterial thrombotic disorders, fibrotic disorders, glaucoma, and neoplastic disorders.

Methods for the identification, production and use of staphylokinase derivatives characterized by a reduced immunogenicity after administration in patients. The derivatives of the invention are obtained by preparing a DNA fragment comprising at least the part of the coding sequence of staphylokinase that provides for its biological activity; performing in vitro site-directed mutagenesis on the DNA fragment to replace one or more codons for wild-type amino acids by a codon for another amino acid; cloning the mutated DNA fragment in a suitable vector; transforming or transfecting a suitable host cell with the vector; culturing the host cell under conditions suitable for expressing the DNA fragment; and purifying the expressed staphylokinase derivative to homogeneity. Preferably the DNA fragment is a 453 bp EcoRI-HindIII fragment of the plasmid pMEX602sakB, (pMEX.SakSTAR), the in vitro site-directed mutagenesis is performed by spliced overlap extension polymerase chain reaction and the mutated DNA fragment is expressed in E. coli strain TG1 or WK6. The invention also relates to pharmaceutical compositions comprising at least one of the staphylokinase derivatives according to the invention together with a suitable excipient, for treatment of arterial thrombosis.

The invention provides an inflatable balloon arteria compressing device. The inflatable balloon arteria compressing device comprises a bearing plate and a puncture unit, the bottom of the bearing plate is provided with a balloon groove inside which a balloon is arranged, the inside of the balloon is provided with a high-pressure gas cylinder, the bearing plate is provided with a clamping unit extending towards the high-pressure gas cylinder, the clamping unit is provided with a puncture nail groove, and when the puncture unit is inserted into the puncture nail groove and achieves expansion fit, the opening of the high-pressure gas cylinder can be pierced to rapidly inflate the balloon. The inflatable balloon arteria compressing device assists a medical worker to compress an arterial puncture bleeding spot, and compared with simple finger compression, can greatly enlarge the effective arteria compressing area, ensure labor-saving, safe and reliable compression and reduce the risk of errhysis of the arterial puncture spot. According to the inflatable balloon arteria compressing device, gas volume in the balloon can be adjusted according to practical conditions, and after the balloonis fixed, the pressure of a pressed position can be adjusted by adjusting the gas volume in the balloon, so that risks of complications caused by excessive compression such as arterial ischemia and artery thrombosis can be reduced.

An assay to assess thrombotic risk in which oxidized lipids comprising phospholipids are utilized as a membrane source in a clotting assay and the results compared to an assay in which unoxidized phospholipid is used as a membrane source in the presence and absence of activated protein C (“APC”). The assay can monitor for the presence of antibodies in the patient which interfere specifically with the anticoagulant function of APC in an oxidation dependent or independent manner. This can indicate the propensity of the patient to experience episodes of vein thrombosis or arterial thrombosis.

The invention discloses a model for arterial thrombosis for animals, which uses a method that collagen coats the thread to copy, wherein collagen induced platelets are gathered irreversibly and consistent with thrombosis in human body. The method comprises the steps of: penetrating the material at the proximal end into the blood vessel at the end by a No.12 fine needle; mastering the dynamics; propelling the fine needle accurately for 3cm in the blood vessel along arterial trend; punching out from the distal end; guiding a No.1 silk thread into the blood vessel and coating the pinhole by surgical glue; and opening the artery clamp at the proximal end 10 minutes later. Compared with common thread-drawing method as an evaluating control group, the improved thread-drawing method provided by the invention is remarkably superior to the common thread-drawing method in the aspects of morphology, FDP, D-dimer, tissue factor and the like. The model for arterial thrombosis for rabbit by the improved thread-drawing method is intuitive, reliable, good in repeatability and high in success rate, can reflect the effect of antithrombotic medicines and is an ideal model for arterial thrombosis for animals.

The invention provides an aneurysm blocking device which is formed by an elastic net-shaped body, the near end of the elastic net-shaped body is folded inwards in the radial direction to be connected with a near-end marking part, the far end of the elastic net-shaped body is folded inwards in the radial direction to be connected with a far-end marking part and folded reversely, the far end of the elastic net-shaped body where the far-end marking part is located extends into the elastic net-shaped body, a double-layer net structure formed through reverse folding forms an expansion part elastic net-shaped body, a single-layer net structure which is not reversely folded forms a neck elastic net-shaped body, and in the self-expansion state, the radial size of the expansion part elastic net-shaped body is gradually increased from the near end to the far end or is increased firstly and then reduced. According to the blocking device capable of effectively treating the aneurysm, the problems that in the prior art, the blocking effect is poor, the operation cost is high, and the operation difficulty is large are solved, the possibility of arterial thrombosis can be reduced, and the risk that the aneurysm top is weak and prone to being broken is reduced.

Provided are compounds, methods, and pharmaceutical compositions for reducing the amount or activity of FXI RNA in a cell or subject, and in certain instances reducing the amount of FXI protein in a cell or subject. Such compounds, methods, and pharmaceutical compositions are useful to prevent, treat, or ameliorate at least one symptom of a thromboembolic condition without a significant increase in a bleeding risk. Such thromboembolic conditions include deep vein thrombosis, venous or arterial thrombosis, pulmonary embolism, myocardial infarction, stroke, thrombosis associated with chronic kidney disease or end-stage renal disease (ESRD), including thrombosis associated with dialysis, or other procoagulant condition. Such symptoms include decreased blood flow through an affected vessel, death of tissue, and death.

Disclosed is the compounds of formula (I), formula (II), formula (la), formula (IIb) or its pharmaceutical acceptable salts, polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising and effective amount of formula (I), formula (II), formula (la), formula (lIb) and may be used to treatment or management of ischemia, stroke, cerebral thrombosis, arterial thrombosis, thrombotic cerebrovascular, cardiovasculard diseases and blood colts.

The present application discloses a new crystal form of ticagrelor, its preparation method and its use in the preparation of a medicament for reducing arterial thrombosis in patients with acute coronary syndrome.

The invention discloses thrombolytic effect of akebiasaponin D and the application thereof. The discovery of the thrombolytic activity of akebiasaponin D has innovativeness. Through anti-mouse pulmonary embolism and anti-rat carotid thrombus formation assay, SAD in vivo thrombolytic activity is researched. The thrombolytic effect has an obvious application prospect in the treatment of thrombotic diseases.

A method for the treatment of atherosclerosis. The method includes the administration of a 32P-labeled agent as a beta emitter, such as 32P-labeled ATP or other 32P-labeled adenine nucleotides, whereby the 32P-labeled agent seeks and then permeates the atherosclerotic plaque en bloc without prior degradation. The accumulation of the 32P-labeled agent in the atherosclerotic plaque is achieved at time points whereby the 32P-labeled agent is cleared from the blood. Thus, radionuclide-labeled adenine nucleotides accumulate with high specificity in atherosclerotic lesions and in the heart. The beta particles (electrons) emitted by the 32P-label have a maximal path distance of about 0.5 cm and their energy preferentially destroy cells present in the atherosclerotic plaque without affecting vessel integrity or inducing arterial thrombosis.

The present invention clearly demonstrates that vWF-collagen interaction plays an important role in acute platelet-dependent arterial thrombus formation and that blockade of vWF-collagen interaction can induce complete abolition of thrombus formation in the injured and stenosed baboon femoral arteries. Accordingly, a blocker of vWF-collagen can be used as a compound for the prevention of acute arterial thrombotic syndromes or to manufacture medicines to prevention of acute arterial thrombotic syndromes.

Provided herein is an animal having a persistent hypercoagulable state by implanting a cell, for example a tumor cell, in which the gene of human tissue factor is implanted to an experimental animal such as a mouse and then growing the cell, thereby persistently supplying human tissue factor to the experimental animal. This animal model is useful for research and development of therapeutic agents for diseases having a persistent hypercoagulable state. Also provided are preventive or therapeutic agents for diseases having a persistent hypercoagulable state, a hypercoagulable state resulting from infections, venous thrombosis, arterial thrombosis, and diseases resulting from the hypertrophy of vascular media, the agent comprising an antibody against human tissue factor (human TF) as an active ingredient.

The present invention is directed to certain amides and heterocyclic compounds. The present invention also relates to uses of these compounds to treat several diseases including autoimmune disorders, cardiovascular disorders, inflammation, central nervous system disorders, arterial thrombotic disorders, fibrotic disorders, glaucoma, and neoplastic disorders.

There is provided the use of a 5-HT2A receptor antagonist to treat or prevent thrombosis, particularly arterial thrombosis, in a human or animal patient. The patient is suitably one who is at risk of bleeding, particularly those about to undergo, or those undergoing, surgery. A preferred 5-HT2A antagonist is thromboserin.